 Mast-Cell Sarcoma
"Mast-Cell Sarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.
| Descriptor ID |
D012515
|
| MeSH Number(s) |
C04.557.450.565.465.124
|
| Concept/Terms |
Mast-Cell Sarcoma- Mast-Cell Sarcoma
- Mast Cell Sarcoma
- Mastocytoma, Malignant
- Malignant Mastocytoma
- Malignant Mastocytomas
- Mastocytomas, Malignant
- Sarcoma, Mast-Cell
- Mast-Cell Sarcomas
- Sarcoma, Mast Cell
- Sarcomas, Mast-Cell
|
Below are MeSH descriptors whose meaning is more general than "Mast-Cell Sarcoma".
Below are MeSH descriptors whose meaning is more specific than "Mast-Cell Sarcoma".
This graph shows the total number of publications written about "Mast-Cell Sarcoma" by people in this website by year, and whether "Mast-Cell Sarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 | | 1997 | 2 | 0 | 2 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 1 | 2 | | 2003 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Mast-Cell Sarcoma" by people in Profiles.
-
Ploss A, Lauvau G, Contos B, Kerksiek KM, Guirnalda PD, Leiner I, Lenz LL, Bevan MJ, Pamer EG. Promiscuity of MHC class Ib-restricted T cell responses. J Immunol. 2003 Dec 01; 171(11):5948-55.
-
Rivas FV, O'Herrin S, Gajewski TF. CD28 is not required for c-Jun N-terminal kinase activation in T cells. J Immunol. 2001 Sep 15; 167(6):3123-8.
-
Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol. 2001 May; 13(5):625-32.
-
Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol. 2000 Dec 01; 165(11):6024-8.
-
Fallarino F, Gajewski TF. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol. 1999 Oct 15; 163(8):4109-13.
-
Fields PE, Finch RJ, Gray GS, Zollner R, Thomas JL, Sturmhoefel K, Lee K, Wolf S, Gajewski TF, Fitch FW. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol. 1998 Nov 15; 161(10):5268-75.
-
Fallarino F, Ashikari A, Boon T, Gajewski TF. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells. Int Immunol. 1997 Sep; 9(9):1259-69.
-
Uyttenhove C, Godfraind C, Lethé B, Amar-Costesec A, Renauld JC, Gajewski TF, Duffour MT, Warnier G, Boon T, Van den Eynde BJ. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int J Cancer. 1997 Jan 27; 70(3):349-56.
-
Gulden PH, Fischer P, Sherman NE, Wang W, Engelhard VH, Shabanowitz J, Hunt DF, Pamer EG. A Listeria monocytogenes pentapeptide is presented to cytolytic T lymphocytes by the H2-M3 MHC class Ib molecule. Immunity. 1996 Jul; 5(1):73-9.
-
Gajewski TF, Fallarino F, Uyttenhove C, Boon T. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol. 1996 Apr 15; 156(8):2909-17.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|